Postpartum depression (PPD) is a prevalent and debilitating condition affecting approximately one in seven women following childbirth. While the etiology of PPD is multifactorial, emerging evidence suggests a potential role for omega-3 polyunsaturated fatty acids in its prevention and management. This review critically evaluates current literature on the association between omega-3 supplementation and PPD, examining evidence regarding its effectiveness, potential mechanisms of action, and implications for clinical practice. A systematic search of electronic databases identified studies investigating omega-3 supplementation in relation to PPD outcomes. Findings suggest that higher omega-3 PUFA status during pregnancy may be associated with a reduced risk of PPD, though results from systematic reviews and meta-analyses remain inconclusive due to methodological variations and study limitations. Mechanistically, omega-3 polyunsaturated fatty acids (PUFAs) exert anti-inflammatory, neuroprotective, and mood-regulating effects, potentially mitigating PPD risk factors. However, further research, including meta-analyses of randomized controlled trials, is needed to elucidate the efficacy of omega-3 supplementation for PPD prevention and management.

Omega-3 fatty acids, Postpartum depression, Polyunsaturated fatty acids, Maternal mental health, Neuroprotective effects, Inflammation modulation, Randomized controlled trials.

Childbirth brings significant physical, emotional, and hormonal changes for women, impacting not only the mother but also her familial and social life. While many experience “baby blues” with mood swings and tearfulness, these usually fade within two weeks. However, about one in seven women develops postpartum depression (PPD), which can have prolonged and severe effects on well-being and infant relationships. PPD often goes undiagnosed due to privacy concerns and fear of stigma, as disclosure may evoke feelings of abandonment or lack of support.[1,2]Top of Form

Omega-3 polyunsaturated fatty acids are crucial for the central nervous system’s growth and development from pregnancy through childhood, impacting normal brain development.[3] They also contribute to the adult brain’s optimal functioning, with docosahexaenoic acid (DHA) making up around 30% of the lipid fraction in the gray matter. Increasing omega-3 intake has shown benefits for neurodegenerative disorders like Alzheimer’s and Parkinson’s disease.[4,5] While rodent studies suggest omega-3 deficiency impairs learning and memory, in humans, a lack of these fatty acids in the diet is associated with a higher risk of various mental disorders, including depression, dementia, schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder.[6-9]

Several studies have investigated the association between omega-3 polyunsaturated fatty acids and PPD.[1,10] Osuna et al.[11] found that higher n-3 polyunsaturated fatty acids (n-3 PUFA) status during early pregnancy was linked to a lower risk of depression at 12 months postpartum among urban Johannesburg women. Similarly, Hoge et al.[12] highlighted the imbalance between omega-6 and omega-3 polyunsaturated fatty acids in early pregnancy as a predictor of PPD, emphasizing the critical role of n-3 PUFA in mental health. Kei Hamazaki et al.[13] reviewed mixed results regarding the association between fish oil intake, omega-3 PUFA, and PPD, with meta-analyses revealing lower n-3 PUFA levels in women with perinatal depression. Additionally, Harauma et al.[14], Møller and Høst et al.[15] and Liu & Wang et al.[16] emphasized the essential role of omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and DHA, in maternal mental health and highlighted the association between seafood consumption and reduced risk of PPD. Nagayasu et al.[17] explored the potential preventive effect of omega-3 PUFA intake against PPD, hypothesizing a protective effect mediated by interleukin 6.[13]

A few meta-analyses and review articles were also studied. The articles discussed the potential benefits of omega-3 polyunsaturated fatty acid supplementation in the treatment of perinatal depression and its impact on maternal and infant health.[8,18] Liu & Wang et al.[16] highlighted the beneficial effects of omega-3 PUFAs on various health conditions during pregnancy, lactation, and infancy, emphasizing the importance of maternal supplementation for fetal growth and development. Zhang et al.[19], Tanskanen & Tuomainen et al.[20], García-Rizo & Sarró et al.[4], Guevara & Barlow et al.[6] and Roel et al.[21] all focused on the efficacy of omega-3 PUFAs specifically for treating paroxysmal nocturnal dyspnea (PND), acknowledging the challenges posed by limited controlled studies and conflicting findings. Liscano & Sanchez-Palacio et al.[18] discussed the prevalence of PPD and the growing interest in alternative treatments, including omega-3 supplementation, which has shown promise due to its anti-inflammatory and neuroprotective properties. Kei Hamazaki et al.[13] Discuss the association between seafood consumption, omega-3 fatty acids, and PPD, highlighting a cross-national ecological analysis revealing that higher national seafood consumption and greater DHA content in breast milk predict lower prevalence rates of PPD, suggesting a potential role for omega-3 supplementation in preventing PPD.[1]Top of FormTop of Form

Overall, while there is evidence supporting the potential benefits of omega-3 PUFAs for perinatal depression, existing systematic reviews and meta-analyses have yielded inconclusive results, potentially due to methodological variations and limitations in study inclusion criteria. Further research, including meta-analyses of all available randomized controlled trials, is needed to clarify the effectiveness of omega-3 PUFAs for perinatal depression and inform clinical decision-making and policy recommendations.[15]

This review examines the susceptibility of women to depression after childbirth and the onset of PPD following childbirth. The main focus is to assess the efficacy of omega-3 polyunsaturated fatty acid supplementation in mitigating depression either during pregnancy or in the postpartum period.

The primary aim of this review is to critically evaluate the current literature on the relationship between omega-3 fatty acid supplementation and PPD. Specifically, the review seeks to address the following research questions:

• What is the evidence regarding the effectiveness of omega-3 supplementation in preventing or alleviating PPD?
• What are the potential mechanisms underlying the association between omega-3 fatty acids and PPD?
• What are the implications of the findings for clinical practice and future research?

Research questions

• How effective is omega-3 fatty acid supplementation in preventing or alleviating PPD among women?
• What biological mechanisms underlie the association between omega-3 fatty acids and PPD?
• What are the clinical implications of omega-3 fatty acid supplementation for managing PPD in high-risk populations?

Research objectives

• To evaluate the effectiveness of omega-3 supplementation in reducing the risk or severity of PPD.
• To explore the anti-inflammatory, neuroprotective, and mood-regulating mechanisms through which omega-3 fatty acids impact PPD.
• To provide evidence-based recommendations for incorporating omega-3 supplementation into clinical guidelines for PPD management.

Literature search strategy: A systematic search of relevant literature was conducted in electronic databases including PubMed, Scopus, and Web of Science. The search strategy utilized a combination of keywords and Medical Subject Headings (MSH) terms related to omega-3 fatty acids, PPD, and related concepts. The search was limited to articles published in English from 2019 to 2024.[22]

Inclusion and exclusion criteria: Studies were included in the review if they met the following criteria:

• Original research articles reporting on the association between omega-3 fatty acid supplementation and PPD.
• Reviews, meta-analyses, commentaries, editorials, or conference abstracts.
• Studies investigating the preventive or therapeutic effects of omega-3 supplementation on PPD outcomes.
• Randomized controlled trials, cohort studies, case-control studies, and cross-sectional studies were considered.
• Studies reporting relevant outcome measures such as depression symptom scores, diagnosis of PPD, or biochemical markers related to depression.
• Studies published in peer-reviewed journals.

Studies were excluded if they were:

• Not relevant to the research question.

Study selection process: Two reviewers screened the titles and abstracts of identified articles to determine their eligibility for inclusion. Full-text articles of potentially relevant studies were then assessed for eligibility based on the inclusion and exclusion criteria.

Data extraction: Data from included studies were extracted using a standardized data extraction form. The extracted information included study characteristics, year of publication, study design, participant characteristics, intervention details, outcome measures, and key findings related to the association between omega-3 supplementation and PPD.[11,17,21]

Data synthesis and analysis: A narrative synthesis approach was employed to summarize and compare the findings of included studies. The synthesis included a qualitative summary of study characteristics, intervention effects, and key findings related to the association between omega-3 supplementation and PPD.

Omega-3 polyunsaturated unsaturated fats, especially eicosapentaenoic corrosive and docosahexaenoic corrosive, have been read up broadly for their expected job in diminishing the gamble of post birth anxiety.[22-27] The component of this impact includes a multi-layered interaction of different natural pathways, adding to the work on mental prosperity during the perinatal period. One key system is the calming properties of omega-3 PUFAs.[9] Diligent irritation has been linked to the advancement of sadness, and omega-3 PUFAs can help regulate the inflammatory response in the body.[28] These unsaturated fats can regulate insusceptible reactions and lessen the creation of favorable to fiery cytokines, possibly easing aggravation related temperament problems.[29] Moreover, omega-3 PUFAs assume a pivotal part in synapse capability.[30]

They are fundamental parts of cell layers in the mind and can impact the degrees of synapses, for example, serotonin and dopamine, which are key regulators of temperament and feelings.[31] By affecting synapse movement, omega-3 PUFAs might contribute to state of mind control and the anticipation of burdensome side effects. Docosahexaenoic corrosive, a sort of omega-3 PUFA, is especially significant for mind design and capability.[9] It upholds brain adaptability, synaptic capability, and neuronal correspondence, which are all basic for mental prosperity.[1,5,14]

Sufficient DHA levels during pregnancy and post pregnancy might advance sound mental health and diminish the gamble of temperament issues like PPD. Furthermore, the cell reinforcement properties of omega-3 PUFAs assume a part in lessening oxidative pressure in the mind.[29] Oxidative pressure has been ensnared in the pathophysiology of wretchedness, and the cell reinforcement impacts of omega-3 PUFAs might offer assurance against this, adding to further developed psychological well-being results. Omega-3 PUFAs also influence inflammation and mood regulation-related gene expression. They can direct the creation and movement of chemicals like cortisol and prostaglandins, which are engaged with pressure reaction and irritation.[32] Mood disorders have been linked to dysregulation of these pathways, and omega-3 PUFAs may help restore balance, lowering the risk of PPD. All in all, the component of activity by which omega-3 PUFAs decline the gamble of post pregnancy anxiety includes a mix of variables, including irritation tweak, synapse capability, cerebrum structure support, oxidative pressure decrease, quality articulation guideline, and chemical equilibrium. These systems, by and large, add to the likely advantages of omega-3 PUFAs in advancing mental prosperity during the perinatal period. Nonetheless, further exploration is expected to completely grasp these perplexing pathways and advance omega-3 PUFA mediations for forestalling and overseeing post-pregnancy anxiety.

The limitations of the reviewed studies are multifaceted and impact the strength and generalizability of the findings. Firstly, the studies included in the review employed various designs, such as prospective cohort studies, observational studies, meta-analyses, and umbrella reviews. This methodological heterogeneity introduces inconsistencies that hinder the ability to draw definitive conclusions. Additionally, there was significant variation in the dosage, duration, and type of omega-3 supplementation used, complicating efforts to compare outcomes and highlighting the need for standardized supplementation protocols. Participant demographics also varied widely across studies, including differences in age, ethnicity, socioeconomic status, and baseline mental health, all of which may influence individual responses to omega-3 supplementation and contribute to inconsistent results. Moreover, the studies utilized diverse outcome measures to assess PPD, such as self-reported depression scales, clinical diagnoses, and biochemical markers, which may affect the reliability and comparability of the findings. Confounding variables, including concurrent treatments, lifestyle factors, dietary habits, and psychosocial support, were not consistently controlled for, potentially compromising the validity of the results. Publication bias is another concern, as studies with positive findings are more likely to be published, possibly leading to an overestimation of omega-3’s effectiveness. Furthermore, many studies focused on specific populations, often from certain geographic regions or with particular risk factors, limiting the applicability of the results to broader, more diverse clinical settings. Lastly, while possible mechanisms linking omega-3 PUFAs to PPD were discussed, the underlying biological pathways remain poorly understood, necessitating further research to clarify these mechanisms and establish causal relationships.

PPD poses significant challenges to maternal well-being and infant development, highlighting the need for effective preventive and therapeutic interventions. Omega-3 PUFAs have emerged as a promising adjunctive therapy for PPD, with evidence suggesting a potential role in reducing depression risk and improving maternal mental health outcomes. Mechanistically, omega-3 PUFAs modulate inflammation, neurotransmitter function, brain structure, oxidative stress, and gene expression pathways implicated in depression pathophysiology. Despite promising findings, the current literature presents inconsistencies and methodological limitations, underscoring the necessity for further rigorous research, including large-scale randomized controlled trials. Clinically, healthcare providers should consider omega-3 supplementation as part of a comprehensive approach to PPD prevention and management, particularly for women at elevated risk. Future studies should aim to clarify optimal dosing, timing, and duration of omega-3 supplementation, as well as identify subpopulations most likely to benefit. Overall, omega-3 PUFAs represent a promising avenue for addressing the complex interplay of biological and psychosocial factors contributing to PPD, holding potential for improving maternal and infant outcomes and enhancing postpartum mental health.

We would like to express our heartfelt gratitude to Dr. Kalsoom Akhtar for her invaluable guidance and support throughout the course of this research. Her expertise and encouragement have been instrumental in shaping this project. We are also deeply thankful to Kinnaird College for Women University, Lahore, for providing us with the resources and platform to conduct this study. Lastly, we extend our sincere appreciation to our families and peers for their unwavering support and encouragement throughout this journey.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Corresponding Author:
Ayesha Masood
Department of Food Science and Human Nutrition
Kinnaird College for Women University, Lahore, Pakistan
Email: ayeshaaamasood.1019@gmail.com

Co-Author:
Haleema Wasif
Department of Food Science and Human Nutrition
Kinnaird College for Women University, Lahore, Pakistan

Ayesha Masood was responsible for conceptualization, methodology, data collection, formal analysis, and writing – including original draft preparation, review, and editing. Haleema Wasif contributed to data collection, data analysis, and review and editing of the manuscript.

Not applicable

Not reported

None

https://doi.org/10.63096/medtigo3084221

Haleema W, Ayesha M. Omega-3 Fatty Acids: Bridging the Gap in Postpartum Depression Research. medtigo J Neurol Psychiatry. 2025;2(2):e3084221. doi:10.63096/medtigo3084221 Crossref